Given that the number of female adolescents aged 12 to 17 years using GLP-1 medications increased 588% between 2020 and 2023 and 659% for female adults aged 18 to 25 years and that women accounted for 76% of those aged 18 to 25 years who were prescribed a GLP-1 medication in 2023, additional research is needed to determine the impact of these medicines on women’s health (eg, pregnancy, breastfeeding, birth control, and endometriosis) [38]. This evidence concerns the gene GLP1R and endometriosis.